Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT
Status:
Completed
Trial end date:
2019-09-06
Target enrollment:
Participant gender:
Summary
1. To evaluate achievement ratio of iPTH,Calcium and phosphorus after taking Cinacalcet HCL
in hemodialysis subjects with mild, moderate and severe SHPT;
2. To explore the impact of Cinacalcet HCL using on the combined use of drugs;
3. To explore the difference of patients who continued or discontinued Cinacalcet HCL in
real-world period from 33rd to 52nd week.
Phase:
Phase 4
Details
Lead Sponsor:
Kyowa Hakko Kirin China Pharmaceutical Co., LTD. Kyowa Hakko Kirin China Pharmaceutical Co.,LTD.